Oncogenic NRG1 fusions: A new hope for targeted therapy in pancreatic cancer
Approximately 8-10% of pancreatic ductal adenocarcinoma cases are KRAS wild-type. In a subset of these tumors, NRG1 gene fusions have been identified as targetable oncogenic drivers, a discovery that highlights the importance of deep molecular characterization …